CEBPA is suppressed in good-risk AML by the leukemic fusion proteins AML1-ETO and CBFβ-SMMHC. Conditional expression of AML1-ETO in U937-tet off-AML1-ETO cells blocks (A) CEBPA mRNA expression assessed by reverse-transcribed polymerase chain reaction, (B) CEBPA protein in Western blot analysis, and (C) CEBPA DNA binding function determined by an ELISA-based assay indicating the spectrophotometric result at 450-nm wavelength,³⁰  whereas expression of CBFβ-SMMHC in U937-tet off-CBFβ-SMMHC (D) does not affect CEBPA mRNA but (E) blocks CEBPA translation by specific induction of the CEBPA mRNA binding protein calreticulin, (F) ultimately leading to blocked CEBPA DNA binding function.³³  Results represent 3 independent experiments. Error bars represent SD. (G) Waterfall diagram presentations of CEBPA DNA binding function assessed by ELISA in 17 AML-M4eo patients with inv(16) (black bars) and in 4 AML-M2 patients with t(8;21) (gray bars) (H) as well as in NK-AML patients with double CEBPA mutations (n = 6) (black bars) and with single CEBPA mutations (n = 2) (gray bars).